Here are the 10-Q quarterly reports from Quantumzyme Corp (QTZM) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow QTZM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full QTZM filings page.
Quantumzyme Corp. reported another pre-revenue quarter for the three months ended October 31, 2025, with no sales and a net loss of $49,868, narrower than the $65,523 loss a year earlier as operating expenses declined.
The balance sheet is extremely weak: cash was just $184 against current liabilities of $490,769, creating a working capital deficit of $490,585 and an accumulated deficit of $5,686,435. Notes payable rose to $268,594, and the company subsequently issued an additional $3,045 promissory note at a 10% interest rate, underscoring its reliance on short-term debt financing.
Management states that these conditions raise “substantial doubt” about the company’s ability to continue as a going concern and notes there are no firm financing agreements in place. The report also discloses material weaknesses in internal controls, including limited staff, lack of segregation of duties, and the absence of an audit committee, although no material legal proceedings are pending and 38,962,050 common shares were outstanding as of December 15, 2025.